NL-OMON30787已完成不适用
The Prostate CARE Study: Capecitabine (Xeloda??) combined with Rhenium-188-HEDP in hormone refractory prostate cancer patients with bone metastases; a Capecitabine phase I dose escalation study and phase II efficacy study. - The Prostate CARE Study
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 33
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •Histologically documented prostate cancer; presence of more than one osteoblastic bone metastases; hormone refractory disease; bone pain; life expectancy of at least 3 months; informed consent.
排除标准
- •Previous chemotherapy within 6 weeks prior to screening; prior treatment with systemic radiotherapeutic bone agent within a specified period; previous external beam radiotherapy within a specified period; active CNS or epidural brain metastases. ANC < 2 10^9/L; Platelet count < 150 10^9/L; Hb < 6 mmol/L; PSA > 5 microgram/L.
研究者
相似试验
进行中（未招募）
不适用
The Prostate CARE Study: Capecitabine (Xeloda®) combined with Rhenium-188-HEDP in hormone refractory prostate cancer patients with bone metastases; a Capecitabine phase I dose escalation study and phase II efficacy study. - The Prostate CARE StudyHormone refractory prostate cancer with painful bone metastasesMedDRA version: 8.1Level: LLTClassification code 10036909Term: Prostate cancer metastaticEUCTR2006-004564-32-NLniversity Medical center Utrecht30
进行中（未招募）
不适用
The Breast CARE Study: Capecitabine (Xeloda®) combined with RHenium-188-HEDP in breast cancer patients with bone metastses; a Re-188-HEDP phase I dose escalation study and phase II efficacy study. - The Breast CARE StudyBreast cancer with painful bone metastases.MedDRA version: 8.1Level: LLTClassification code 10027475Term: Metastatic breast cancerEUCTR2006-004008-38-NLniversity Medical Center Utrecht40
已完成
不适用
The Breast CARE Study: Capecitabine (Xeloda) combined with Rhenium-188-HEDP in breast cancer patients with bone metastases; a Re-188-HEDP phase I dose escalation study and phase II efficacy study.breast cancer that has spread to the bone10027476NL-OMON30358Academisch Medisch Centrum33
进行中（未招募）
1 期
Phase II trial of capecitabine (Xeloda®) + nab-paclitaxel (Abraxane®) in patients with metastatic pancreatic cancerEUCTR2013-001714-15-ATMed. Univ. Wien, Klinik f. Innere Med. I, Onkologie30
进行中（未招募）
不适用
Prospective phase II trial using Capecitabine and Trastuzumab for therapy of female patients with cerebral metastasizing, HER2-overexpressing breast cancer - HERXECNS-metastasizing HER2-overexpressing breast cancerMedDRA version: 9.1Level: PTClassification code 10057654Term: Breast cancer femaleMedDRA version: 9.1Level: PTClassification code 10006202Term: Breast cancer stage IVEUCTR2007-003634-42-DEKlinikum der Universität München, Standort Großhadern